A new adjuvant treatment, osimertinib (Tagrisso), has been approved for patients with non-small cell lung cancer whose tumors have certain mutations.The most common adverse effects of treatment are leukopenia, lymphopenia, thrombocytopenia, diarrhea, anemia, rash, musculoskeletal pain, nail toxicity, neutropenia, dry skin, stomatitis, fatigue, and cough.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000742492.40886.52 | DOI Listing |
Publication Analysis
Top Keywords
lung cancer
8
adjuvant drug
4
drug lung
4
cancer adjuvant
4
adjuvant treatment
4
treatment osimertinib
4
osimertinib tagrisso
4
tagrisso approved
4
approved patients
4
patients non-small
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!